← Leaderboards
Pedro Cabrales
University Of Maryland Baltimore
$3,324,388
Attributed
$10,232,158
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,232,158 · 5
By mechanism
R01$9,832,408 · 4
R56$399,750 · 1
Top collaborators
- Andre Francis Palmer18 shared
- Paul Werner Buehler8 shared
- David Charles Irwin8 shared
- Pravin Tp Kaumaya4 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Gary Fiskum$7,297,793
- Feyruz Virgilia Rassool$1,878,287
- Angela None Wilks$10,746,070
- Vincent Michael Bruno$8,178,836
Others in their field
Top investigators on “Hemoglobin”
- John M Lachin · George Washington University$134,552,372
- David M Nathan · Massachusetts Institute Of Technology$123,579,624
- Rose A Gubitosi-Klug · Case Western Reserve University$60,881,424
- Rohit Varma · University Of Southern California$56,341,998
- Anastassios G Pittas · Tufts Medical Center$38,762,359
- Lihong Wang · Texas A&M University System$33,028,686
Research focus
HemoglobinPreventOrganProteinsCellsHemeAffinityErythrocytesToxic EffectPhysiologicalHypertensionTissuesIn VivoVasoconstrictionHemodynamicsBlood VesselsBaseAttenuatedAnimal ModelResponseIronAdverse EffectsCardiacAnimals
Grant awards (18)
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$631,536
R01 · FY2025 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$629,898
R01 · FY2024 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$625,741
R01 · FY2024 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$653,723
R01 · FY2023 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$646,411
R01 · FY2023 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$701,968
R01 · FY2022 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$656,753
R01 · FY2022 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$703,990
R01 · FY2021 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$695,646
R01 · FY2020 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$708,669
R01 · FY2019 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$371,545
R01 · FY2019 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$718,085
R01 · FY2018 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$457,459
R01 · FY2018 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$752,718
R01 · FY2017 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$457,644
R01 · FY2017 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$31,923
R01 · FY2017 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$388,699
R01 · FY2016 · HL
Attenuating the Oxidative and Myocardial Toxicity of Polymerized Hemoglobins$399,750
R56 · FY2014 · HL